11,000 Shares in Celgene Co. (CELG) Purchased by Kamunting Street Capital Management L.P.

Kamunting Street Capital Management L.P. purchased a new position in Celgene Co. (NASDAQ:CELG) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 11,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,148,000. Celgene accounts for about 0.8% of Kamunting Street Capital Management L.P.’s portfolio, making the stock its 22nd largest holding.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CELG. Lockheed Martin Investment Management Co. lifted its stake in Celgene by 40.0% in the 3rd quarter. Lockheed Martin Investment Management Co. now owns 14,000 shares of the biopharmaceutical company’s stock valued at $2,041,000 after buying an additional 4,000 shares in the last quarter. Sigma Planning Corp lifted its stake in Celgene by 399.8% in the 3rd quarter. Sigma Planning Corp now owns 19,834 shares of the biopharmaceutical company’s stock valued at $2,892,000 after buying an additional 15,866 shares in the last quarter. Howland Capital Management LLC lifted its stake in Celgene by 8.6% in the 3rd quarter. Howland Capital Management LLC now owns 156,853 shares of the biopharmaceutical company’s stock valued at $22,872,000 after buying an additional 12,455 shares in the last quarter. Haverford Trust Co. purchased a new stake in Celgene in the 3rd quarter valued at approximately $378,000. Finally, Alliance Wealth Management Group purchased a new stake in Celgene in the 3rd quarter valued at approximately $360,000. Institutional investors and hedge funds own 78.63% of the company’s stock.

Shares of NASDAQ CELG opened at $89.74 on Friday. Celgene Co. has a 12-month low of $84.25 and a 12-month high of $147.17. The firm has a market capitalization of $67,274.59, a P/E ratio of 13.12, a P/E/G ratio of 0.60 and a beta of 1.49. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 4.80.



Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. During the same period in the prior year, the firm earned $1.61 EPS. The firm’s quarterly revenue was up 16.9% compared to the same quarter last year. analysts forecast that Celgene Co. will post 7.66 earnings per share for the current year.

Celgene announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, February 14th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

A number of research firms recently issued reports on CELG. Cantor Fitzgerald set a $112.00 target price on Celgene and gave the company a “hold” rating in a research note on Tuesday, January 23rd. ValuEngine lowered Celgene from a “hold” rating to a “sell” rating in a research note on Thursday. Deutsche Bank set a $110.00 target price on Celgene and gave the company a “hold” rating in a research note on Monday, January 8th. Robert W. Baird reissued a “hold” rating and set a $92.00 price target on shares of Celgene in a research note on Thursday, March 1st. Finally, SunTrust Banks set a $127.00 price target on Celgene and gave the stock a “buy” rating in a research note on Monday, January 8th. Four analysts have rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $127.68.

In other news, Director Ernest Mario sold 13,370 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $94.49, for a total transaction of $1,263,331.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark J. Alles bought 3,260 shares of the stock in a transaction dated Thursday, February 8th. The shares were acquired at an average price of $91.90 per share, with a total value of $299,594.00. Following the completion of the purchase, the insider now directly owns 178,904 shares of the company’s stock, valued at $16,441,277.60. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 41,120 shares of company stock valued at $3,879,509. 0.95% of the stock is owned by insiders.

WARNING: “11,000 Shares in Celgene Co. (CELG) Purchased by Kamunting Street Capital Management L.P.” was originally reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://dakotafinancialnews.com/2018/04/13/11000-shares-in-celgene-co-celg-purchased-by-kamunting-street-capital-management-l-p.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply